### Genetic associations with human longevity are enriched for 1 oncogenic genes 2

3 4

5

Junyoung Park, PhD<sup>1</sup>, Andrés Peña-Tauber, BA<sup>1</sup>, Lia Talozzi, PhD<sup>1</sup>, Michael D. Greicius, 6 MD<sup>1\*</sup>, Yann Le Guen, PhD<sup>2\*</sup>

7 8

### 9 Affiliations

- <sup>1</sup>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 10 11 94305. USA.
- <sup>2</sup>Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, CA, 12 13 94304, USA.
- 14
- 15

### **Corresponding authors:** 16

- Junyoung Park 17
- 18 Stanford Neuroscience Health Center
- 19 290 Jane Stanford Way,
- 20 Stanford, CA 94305-5090
- 21 jpark01@stanford.edu
- 22 (650) 666-2696
- 23
- 24
- \* These authors contributed equally 25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 26 Abstract

### 27

28 Human lifespan is shaped by both genetic and environmental exposures and their interaction. 29 To enable precision health, it is essential to understand how genetic variants contribute to

- 30 earlier death or prolonged survival. In this study, we tested the association of common genetic
- 31 variants and the burden of rare non-synonymous variants in a survival analysis, using age-at-
- 32 death (N = 35,551, median [min, max] = 72.4 [40.9, 85.2]), and last-known-age (N = 358,282,
- 33 median [min, max] = 71.9 [52.6, 88.7]), in European ancestry participants of the UK Biobank.
- 34 The associations we identified seemed predominantly driven by cancer, likely due to the age
- 35 range of the cohort. Common variant analysis highlighted three longevity-associated loci:
- 36 APOE, ZSCAN23, and MUC5B. We identified six genes whose burden of loss-of-function 37 variants is significantly associated with reduced lifespan: TET2, ATM, BRCA2, CKMT1B,
- 38 BRCA1 and ASXL1. Additionally, in eight genes, the burden of pathogenic missense variants
- 39 was associated with reduced lifespan: DNMT3A, SF3B1, CHL1, TET2, PTEN, SOX21, TP53
- 40 and SRSF2. Most of these genes have previously been linked to oncogenic-related pathways
- 41 and some are linked to and are known to harbor somatic variants that predispose to clonal
- 42 hematopoiesis. A direction-agnostic (SKAT-O) approach additionally identified significant
- associations with Clorf52, TERT, IDH2, and RLIM, highlighting a link between telomerase 43
- 44 function and longevity as well as identifying additional oncogenic genes.
- 45 Our results emphasize the importance of understanding genetic factors driving the most
- 46 prevalent causes of mortality at a population level, highlighting the potential of early genetic
- 47 testing to identify germline and somatic variants increasing one's susceptibility to cancer
- 48 and/or early death.

#### 49 Introduction

50 Longevity is a complex trait influenced by both genetic and environmental factors and their 51 interactions [1]. According to previous studies, genetics accounts for as much as 40% of the 52 heritability of longevity [2-4]. Identifying the genetic variants that contribute to earlier death 53 or prolonged survival can highlight key biological pathways linked to lifespan and inform 54 genetic testing for general health and screening and enabling precision health. Previous 55 genome-wide association studies (GWAS) have identified over 20 associated loci including 56 APOE [5, 6], CHRNA3/5 [7], HLA-DQA1 and LPA [8]. Recently, a burden analysis of proteintruncating variants from whole-exome sequencing (WES) data identified four additional genes 57 58 (BRCA2, BRCA1, ATM, and TET2) linked to reduced lifespan [9]. However, most previous 59 research on lifespan genetics has predominantly used proxy data, such as parents' age at death, 60 due to a lack of proband lifespan data. While proxy-based GWAS have been necessary for large cohorts of primarily middle-aged individuals with limited mortality data, this approach 61 62 restricts the accuracy and scope of findings, as it may fail to comprehensively capture the 63 genetic influences that directly impact an individual's lifespan [10]. On the other hand, some 64 studies have employed logistic regression models on cases of extreme longevity and younger 65 controls [11-13]. This approach may offer new insights by focusing on exceptionally longlived individuals, yet they can be limited and costly. Moreover, replication of borderline 66 significant variants remains an issue due to varying case definitions across studies, with some 67 68 defining cases as individuals who survive to ages beyond 90 or 100 years or using the 90th or 69 99th survival percentiles as the age cutoff.

- 70 In this study, we carried out a genetic analysis of direct mortality data in the UK Biobank, the
- 71 genetic database with the largest number of reported deaths (35,551 subjects) and aged
- 72 individuals (344,237 subjects over 60 years old). To assess the association of genetic variants
- 73 with longevity in a survival analysis, we performed GWAS of common variants imputed from
- 74 microarray data as well as burden/sequence kernel association test-optimized (SKAT-O)
- 75 association of rare non-synonymous variants from WES data.
- 76

### 77 Results 78

#### 79 Genome-wide association analyses in imputed array data

Our GWAS assessed 6,127,227 common variants (minor allele frequency (MAF)  $\geq$  1%) using 80 81 Martingale residuals on 393,833 individuals including 35,551 deceased subjects (mean age at 82 death: 71.2 years) and 358,282 living subjects (mean current age: 70.7) from UKB 83 (Supplementary Table 1) [14]. Two loci reached genome-wide significance (GWS) (p <84  $5.0 \times 10^{-8}$ ) on chromosomes 19 and 6 (Figure 1A). On chromosome 19, rs429358 was the lead variant at the APOE locus ( $\beta = 0.013$ ,  $p = 6.4 \times 10^{-47}$ , MAF = 15.6%). We tested whether 85 86 the presence of APOE-c4 was enriched in certain primary causes of death. Among the top four causes of death, each representing over 5% of total deaths (Figure 1B), only those due to 87 88 'Diseases of the circulatory system' (Chi-square  $p=1.6 \times 10^{-16}$ ) and 'Diseases of the nervous 89 system'  $(p=1.1 \times 10^{-71})$  showed a significant enrichment in the proportion of  $\varepsilon 4$  carriers 90 compared to the prevalence of  $\varepsilon 4$  carriers among all subjects (Figure 1C). In the chromosome 91 6 locus, overlapping ZSCAN23, two variants were GWS: rs6902687, located 2.2 kb upstream 92 of the transcription start site (TSS), and rs13190937 situated in the 5' untranslated region 93 (UTR) (rs6902687 C:  $\beta = 0.004$ ,  $p = 1.5 \times 10^{-8}$ , MAF = 36.6%; rs13190937 A: = 0.004, p = p 94 =  $1.5 \times 10^{-8}$ , MAF = 36.6%, Figure 1D). To explore a potential regulatory function for variants 95 at the ZSCAN23 locus, we investigated whether the lead SNPs were expression quantitative 96 trait loci (eOTLs) in the Genotype-Tissue Expression Project (GTEx) v8 database. rs13190937 97 was significantly associated with increased ZSCAN23 expression in pancreatic tissue and the

medRxiv preprint doi: https://doi.org/10.1101/2024.07.30.24311226; this version posted August 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

98 longevity GWAS signal colocalized with the ZSCAN23 expression quantitative trait loci 99 (eQTL) (posterior probability of colocalization (PP4) = 0.94; Figure 1E). Phenome-wide association study analysis (PheWAS) using PheWeb [15] shows that the main associations of 100 101 rs13190937 are with celiac disease and intestinal malabsorption ( $p = 1.8 \times 10^{-57}$ ) 102 (Supplementary Figure 1).

In sex-stratified GWAS (180,970 males and 212,863 females), the APOE locus was again 103

- 104 linked to longevity in both males and females (Supplementary Table 1 and Supplementary
- 105 Figure 2A and B). In males, we observed an additional GWS association for rs35705950 T
- located between MUC5AC and MUC5B on chromosome 11 ( $\beta = 0.01$ ,  $p = 2.1 \times 10^{-8}$ , MAF = 106 11.2%) (Supplementary Figure 2C), while no additional association was found in females. This 107
- 108 variant was notably linked to increased *MUC5B* expression in lung tissue with the longevity
- 109 GWAS signal aligning with a MUC5B eQTL (PP4 = 0.99; Supplementary Figure 2D). We also
- 110 confirmed through PheWAS that rs35705950 is associated with a diagnosis of pulmonary
- 111 fibrosis ( $p=4.4 \times 10^{-13}$ ) and "Other interstitial pulmonary diseases with fibrosis" listed as
- primary cause of death ( $p=1.7 \times 10^{-5}$ ), and Illness of the father "Lung cancer" ( $p=2.1 \times 10^{-4}$ ), 112
- but not with the mother's (p=0.07) (Supplementary Figure 2E). 113
- 114

### 115 Gene-based rare variant association analyses in whole-exome data

116 Among 26,230,624 variants with MAF < 1%, 1,830,070 variants (17,174 genes) were 117 annotated as loss-of-function (LoF) or missense variants. Of these, 628,362 were predicted LoF 118 variants (17,071 genes with a median of 28 variants per gene), 985,950 were missense variants 119 predicted as damaging by AlphaMissense (15,891 genes with a median of 47 variants per gene),

- 120 and 349,791 were missense variants predicted as damaging by rare exome variant ensemble
- 121 learner (REVEL) (12,219 genes with a median of 12 variants per gene). Of variants classified
- 122 by each, 23.7% of AlphaMissense and 66.9% of REVEL variants were also pathogenic by the
- 123 other classifier.

We identified six genes whose burden of LoF variants is significantly associated with reduced 124 lifespan: TET2 ( $p=3.8 \times 10^{-30}$ ), ATM ( $p=6.0 \times 10^{-10}$ ), BRCA2 ( $p=1.3 \times 10^{-34}$ ), CKMT1B 125

- $(p=4.5 \times 10^{-7})$ , BRCA1  $(p=4.9 \times 10^{-12})$  and ASXL1  $(p=2.3 \times 10^{-44})$  (Figure 2A and Table 126
- 1). All of these but CKMT1B also showed gene-wide significance in a direction-agnostic 127
- (SKAT-O) approach (Supplementary Figure 3A). Additionally, in eight genes, the burden of 128 129 missense variants predicted as pathogenic by AlphaMissense was associated with reduced
- lifespan: DNMT3A ( $p=1.4 \times 10^{-9}$ ), SF3B1 ( $p=6.7 \times 10^{-12}$ ), CHL1 ( $p=5.0 \times 10^{-7}$ ), TET2 130
- $(p=4.2\times10^{-7})$ , PTEN  $(p=1.0\times10^{-8})$ , SOX21  $(p=2.9\times10^{-8})$ , TP53  $(p=3.1\times10^{-15})$  and 131
- 132 SRSF2 ( $p=9.8 \times 10^{-89}$ ) (Figure 2B). Lastly, three genes showed gene-wide significance for
- burden of missense variants predicted by REVEL: DNMT3A ( $p = 6.6 \times 10^{-9}$ ), PTEN 133
- $(p=6.6 \times 10^{-8})$ , and TP53  $(p=6.2 \times 10^{-9})$  (Supplementary Figure 4 and Supplementary Table 134
- 2). SKAT-O identified additional associations with pathogenic missense variants predicted by 135
- AlphaMissense in *Clorf52* ( $p=2.1 \times 10^{-7}$ ), *IDH2* ( $p=5.3 \times 10^{-39}$ ) and *RLIM* ( $p=3.7 \times 10^{-9}$ ) 136
- (Supplementary Figure 3B), and by REVEL in TERT ( $p=8.1 \times 10^{-10}$ ) (Supplementary Figure 137
- 138 3C and Supplementary Table 2).
- For sex-specific gene-based analysis, an additional six genes not identified in the whole-cohort 139
- 140 analysis showed gene-wide significance in males by either burden or SKAT-O: CDKN1A and
- 141 PTPRK (LoF); COA7 and TG (AlphaMissense); NMNAT2 and PITRM1 (REVEL)
- 142 (Supplementary Figure 5A, 6A and Supplementary Table 3). In females, we identified three
- 143 additional genes associated with reduced lifespan: PORCN (AlphaMissense); UGT1A8 and
- 144 OLIG1 (REVEL) (Supplementary Figure 5B, 6B and Supplementary Table 4).
- 145
- 146 Gene-burden survival analysis

147 For the 13 gene-wide significant genes in the burden analyses, we assessed the association of 148 variant carrier status with lifespan using Cox proportional hazards regression. Carriers of LoF 149 variants in six genes were associated with decreased survival compared to non-carriers: *CKMT1B* (HR=3.9,  $p=2.1 \times 10^{-6}$ ), *ASXL1* (HR=2.2,  $p=3.8 \times 10^{-26}$ ) (Figure 3A), *TET2* 150  $(HR=1.7, p=2.7 \times 10^{-18}), ATM (HR=1.7, p=2.5 \times 10^{-10}), BRCA2 (HR=2.4, p=1.1 \times 10^{-40}),$ 151 and BRCA1 (HR =2.2,  $p=1.0 \times 10^{-12}$ ) (Supplementary Figure 7A). Similarly, carriers of 152 AlphaMissense-predicted pathogenic variants exhibited significantly earlier mortality 153 154 compared to non-carriers on the following genes: DNMT3A (HR=1.4,  $p=2.0 \times 10^{-7}$ ), SF3B1 (HR=2.1,  $p=2.0 \times 10^{-8}$ ), CHL1 (HR=1.3,  $p=3.4 \times 10^{-7}$ ), PTEN (HR=4.2,  $p=3.4 \times 10^{-10}$ ), 155 SOX21 (HR=1.9,  $p=5.2 \times 10^{-8}$ ), TP53 (HR=3.7,  $p=1.7 \times 10^{-13}$ ), SRSF2 (HR=5.0,  $p=2.4 \times 10^{-13}$ ) 156  $10^{-52}$ ) (Figure 3B) and *TET2* (HR=1.5,  $p=3.8 \times 10^{-6}$ ) (Supplementary Figure 7B). Carriers 157 of pathogenic variants predicted by REVEL showed similar trends: DNMT3A (HR=1.5, 158  $p = 1.9 \times 10^{-6}$ ), PTEN (HR=5.3,  $p = 1.3 \times 10^{-10}$ ), and TP53 (HR=2.4,  $p = 6.6 \times 10^{-8}$ ) 159 (Supplementary Figure 7C). 160

To explore the contribution of individual rare variants to mortality in each gene-wide 161 162 significant gene in the burden and SKAT-O tests, we conducted Cox proportional hazards regression for each variant with a minor allele count (MAC) of three or more (Table 2). In total, 163 164 587 variants including LoF, AlphaMissense and REVEL variants were examined. After 165 applying a Bonferroni correction for multiple testing, setting the significance threshold at  $8.5 \times 10^{-5}$  (0.05/587), we identified significant associations with reduced lifespan for four LoF 166 variants: rs370735654 in TET2 (MAC=17, HR=7.0, p=5.6×10<sup>-9</sup>), rs587779834 in ATM 167 (MAC=113, HR=2.5,  $p=2.7 \times 10^{-5}$ ), rs80359520 in *BRCA2* (MAC=10, HR=6.1,  $p=1.8 \times 10^{-5}$ ) 168 10<sup>-6</sup>), rs750318549 in ASXL1 (MAC=201, HR=2.5, p=2.3×10<sup>-15</sup>). Additionally, significant 169 associations with AlphaMissense variants were noted in six genes, impacting lifespan: 170 rs769009649 in Clorf52 (MAC=62, HR=3.2,  $p=7.4 \times 10^{-7}$ ), rs147001633 in DNMT3A 171 (MAC=269, HR=1.8,  $p=3.7 \times 10^{-5}$ ), rs377023736 in SF3B1 (MAC=12, HR=6.0, p=8.5172 × 10<sup>-8</sup>), rs116421102 in CHL1 (MAC=1,842, HR=1.3, p=2.5× 10<sup>-5</sup>), rs121913502 in IDH2 173  $(MAC=45, HR=5.7, p=1.0 \times 10^{-20})$ , rs11540652 in TP53  $(MAC=5, HR=10.0, p=6.6 \times 10^{-8})$ 174 and rs751713049 in SRSF2 (MAC=51, HR=5.8,  $p=1.9 \times 10^{-26}$ ). For missense variants 175 predicted by REVEL, rs1043358053 in TERT (MAC=5, HR=11.9,  $p=7.4 \times 10^{-5}$ ) and 176 177 rs11540652 in TP53 were significantly linked to reduced lifespan (Supplementary Table 5).

178

#### 179 **Phenome-wide association studies**

For the nine novel longevity genes identified in the burden test (CKMT1B, ASXL1, DNMT3A, 180 181 SF3B1, CHL1, PTEN, SOX21, TP53 and SRSF2), we examined the burden of LoF or 182 pathogenic missense variants through PheWASs across 1,670 UKB phenotypes including 183 disease occurrences derived from electronic health record, self-reported family history, and physical measures (Supplementary Figure 8). The burden of LoF variants in ASXL1 and 184 185 AlphaMissense variants in DNMT3A, SF3B1, PTEN, TP53 and SRSF2 were strongly linked to 186 an increased risk of leukemia: acute myeloid leukemia (ASXL1: Odds Ratio (OR)=1.05;  $p=8.6 \times 10^{-170}$ ; DNMT3A: OR=1.03,  $p=2.1 \times 10^{-150}$ ; SRSF2: OR=1.3,  $p=1.2 \times 10^{-195}$ ; 187 *TP53*: OR=1.05,  $p=4.7 \times 10^{-35}$ ), monocytic leukemia (*DNMT3A*: OR=1.01,  $p=2.5 \times 10^{-9}$ ), 188 chronic lymphoid leukemia (SF3B1: OR=1.07,  $p=4.1 \times 10^{-68}$ ) and acute lymphoid leukemia 189 (*PTEN*: OR=1.01,  $p=2.1 \times 10^{-14}$ ). Additionally, the burden of LoF in *CKMT1B* was 190 associated with hypopharynx cancer (OR=1.03,  $p=3.9 \times 10^{-26}$ ), vertiginous syndromes 191  $(OR=1.03, p=3.0 \times 10^{-17})$  and salivary glands cancer  $(OR=1.03; p=3.2 \times 10^{-12})$ . SOX21 192 burden was associated with increased acne (OR=1.01,  $p=6.9 \times 10^{-7}$ ) and spinocerebellar 193

disease (OR=1.01,  $p=2.3 \times 10^{-6}$ ). 194

medRxiv preprint doi: https://doi.org/10.1101/2024.07.30.24311226; this version posted August 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

### 195

### 196 Somatic mutation and clonal hematopoiesis of indeterminate potential

197 We computed the variant allelic fraction (VAF) per carrier for each variant included in the 198 analysis. Generally, germline variants have a mean VAF close to 50%, while somatic variants' 199 mean VAF will be lower [16]. Thus, when an association is linked to clonal hematopoiesis of 200 indeterminate potential (CHIP), we expect the distribution of VAF to be left-shifted compared 201 to a normal distribution centered at VAF = 50%. Considering LoF variants, TET2 (mean VAF 202 across variants [95% bootstrap confidence interval for the mean VAF] = 0.33 [0.31,0.34]) and 203 ASXL1 (mean VAF =0.32 [0.31,0.33]) burden test associations are supported by variants with 204 a left-shifted VAF distribution (Supplementary Table 6, Supplementary Figure 9A). Similarly, 205 considering pathogenic Alpha Missense variants, in DNMT3A (mean VAF= 0.24 [0.23-0.24]), 206 TET2 (mean VAF=0.36 [0.34,0.38]), TP53 (mean VAF=0.28 [0.24,0.34]), SRSF2 (mean 207 VAF=0.30 [0.28,0.31]), SF3B1 (mean VAF=0.31 [0.26,0.37]) and CHL1 (mean 208 VAF=0.37[0.28-0.45]) are also left-shifted and the observed associations may be linked to 209 CHIP (Supplementary Table 5, Supplementary Figure 9B).

- 210
- 211 **Methods** 212

### 213 **Study participants**

214 The UKB is a large population-based longitudinal cohort study with recruitment from 2006 to 215 2010 in the United Kingdom [17]. In total, 502,664 participants aged 40-69 years were 216 recruited and underwent extensive phenotyping including health and demographic 217 questionnaires, clinic measurements, and blood draw at one of 22 assessment centers, of whom 218 468,541 subjects have been genotyped by both SNP array and WES.

219 We restricted our analysis to 393,833 individuals who self-reported their ethnic background as 220 'white British' and were categorized as European ancestry based on genetic ethnic grouping 221 (Field: 21000). Among them, 35,551 subjects were reported deceased, and their ages at death 222 were recorded from the UK Death Registry (Field: 40007). For the other 358,282 subjects 223 without death records, we assumed they were still alive by the latest censoring date (November 224 30, 2023). We determined their last known ages by subtracting their year and month of birth 225 (Field: 33) from the censoring date. 226

### 227 SNP array genotyping and QC

228 A total of 488,000 UKB participants were genotyped using one of two closely related 229 Affymetrix microarrays (UKB Axiom Array or UK BiLEVE Axiom Array) for ~820,000 230 variants. Quality control (QC), phasing, and imputation were performed as described 231 previously [18]. Briefly, the genotyped dataset was phased and imputed into UK10K, 1000 232 Genomes Project phase 3, and Haplotype Reference Consortium reference panels, resulting in 233 approximately 97 million variants. Additionally, we removed SNPs with imputation quality 234 score < 0.3, genotype missing rate > 0.05, minor allele frequency (MAF) < 1%, and Hardy-235 Weinberg equilibrium  $p < 1.0 \times 10^{-6}$ . 236

### 237 Genome-wide association studies

238 We performed linear regression models using PLINK v2.0 [19] to test the association of 239 common variants (MAF  $\geq$  1%) with longevity for the entire cohort, as well as stratified by sex. 240 For all three analyses, we used Martingale residuals calculated using the Cox proportional 241 hazards model as the outcome variable. The procedure for calculating Martingale residuals was

242 as follows. First, a Cox proportional hazards model [20] was fitted without genotype,

243 
$$H(t|z) = H_0(t)e^{Z\beta'}$$

medRxiv preprint doi: https://doi.org/10.1101/2024.07.30.24311226; this version posted August 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

244 where  $H_0(t)$  is the baseline hazard function at time point t given the last-known age and 245 dead/alive status,  $Z = [Z_1, ..., Z_k]$  is a covariate matrix, and  $\beta = [\beta_1, ..., \beta_k]$  is a coefficient matrix for Z. Here, we included sex and the first five principal components (PC) as covariates, 246

247 but for sex-specific analyses, sex was excluded. Then, Martingale residuals were calculated as: 'β 248

$$\widehat{M}_i = \delta_i - \widehat{H}_0(t)e^Z$$

249 where  $\delta_i$  is the dead/alive status (0=alive, 1=dead) of the *i*th subject and  $\hat{\beta}$  is the estimated 250 coefficient matrix. We adapted the *coxph* function from the *survival* (v.3.6.4) R package [21] 251 to compute the Martingale residuals. Genome-wide significance threshold was set at the 252 standard GWAS level ( $p=5.0 \times 10^{-8}$ ). We used *LocusZoom* [22] to generate regional plots 253 and Python v.3.7 to create Manhattan plots.

254

### 255 Gene expression and colocalization analysis

256 To evaluate the effect of the significant loci identified in our GWAS, we examined expression 257 quantitative trait loci (eQTLs) across 49 tissues having at least 73 samples from the Genotype-258 Tissue Expression Project (GTEx) version 8 [23]. Bayesian colocalization analysis was 259 employed using the COLOC package (v.5.2.3) [24] in R and the posterior probability of colocalization (PP4) was calculated between GWAS findings and eQTL associations within a 260 261 1 megabase (Mb) window. Additionally, colocalization was visualized using the 262 locuscompareR package [25].

263

### 264 Whole-exome sequencing and QC

Whole exome sequencing (WES) data was available for 469,835 UKB participants. The dataset 265 266 was generated by the Regeneron Genetics Center [26]. Details about the production and QC 267 for the WES data are described previously [26]. We restricted the WES analysis to rare variants (MAF < 1%).268

269

#### 270 **Rare variant annotation**

271 Rare variants in WES data were annotated using Variant Effect Predictor (v. 112) provided by

- 272 Ensembl [27]. We defined LoF variants as those with predicted consequences: splice acceptor,
- 273 splice donor, stop gained, frameshift, start loss, stop loss, transcript ablation, feature elongation,
- 274 or feature truncation. Missense variants were annotated using AlphaMissense [28] and REVEL
- 275 [29] plugins and included if they had an AlphaMissense score  $\geq 0.7$  or REVEL score  $\geq 0.75$ .

276 All annotation was conducted based on GRCh38 genome coordinates.

- 277 278 Gene-based rare variant association studies
- 279 For testing groups of rare variants, genotype matrices were first transformed into a binary 280 variable describing whether samples carry a variant of a given class as follows:

281 
$$G_{i} = \begin{cases} 1, & \text{if } \sum_{j=1}^{k} g_{ij} > 0 \\ 0, & \text{if } \sum_{j=1}^{k} g_{ij} = 0 \end{cases},$$

Where  $g_{ij}$  is the minor allele count observed for subject *i* at variant *j* in the gene and *k* is the 282 283 number of variants in the gene. We carried out two gene-based tests: Burden test and sequence 284 kernel association test-optimized (SKAT-O) [30]. The burden test is a mean-based test that 285 assumes the same direction of effects for all variants within a gene. On the other hand, SKAT-286 O employs a weighted average of the burden test and SKAT [31], the latter a variance-based 287 test that does not lose power when variants have opposing directions of effect.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.30.24311226; this version posted August 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

288 Association tests were performed for each gene and rare variant class, including separately LoF 289 variants, missense variants with an AlphaMissense score  $\geq 0.7$ , and missense variants with a 290 REVEL score  $\geq 0.75$ , using Martingale residuals as the phenotype as in the common variant 291 analyses. We excluded genes with fewer than 10 variant carriers to ensure the reliability of our 292 analyses. A gene-wide significance threshold was established at  $p=7.4 \times 10^{-7}$  based on the 293 Bonferroni method accounting for the number of genes, variant classes, and statistical methods. 294 Gene-based analyses were carried out using the SKAT package (v.2.2.5) in R.

295 To characterize the impacts of gene burden in significant genes, we compared lifespan survival 296 depending on gene burden using Kaplan-Meier survival curves, log-rank tests, and Cox 297 proportional hazard regression analyses. Additionally, we performed Cox proportional hazards 298 regression to assess the effect of each rare variant in a gene. The survival (v.3.6.4) package in 299 R was utilized for the survival analysis.

300

#### 301 Phenome-wide association studies

302 For gene-wide significant genes, we conducted phenome-wide association studies (PheWAS) 303 of variant carrier status across 1,670 phenotypes in the UKB derived from binary, categorical, 304 and continuous traits. Phenotypes included the International Classification of Disease 10 (ICD-10) codes, family history (e.g. father's illness, father's age at death), blood count (e.g. 305 306 white blood cell count), blood biochemistry (e.g. Glucose levels), infectious diseases (e.g. pp 307 52 antigen for Human Cytomegalovirus), physical measures (e.g. BMI), cognitive test (e.g. 308 pairs matching) and brain measurements (e.g. subcortical volume of hippocampus). For ICD-309 10 codes, we excluded phenotypes from the following ICD-10 chapters: 'Injuries, poisonings, 310 and certain other consequences of external causes' (Chapter XIX), 'External causes of 311 morbidity and mortality' (Chapter XX), 'Factors influencing health status and contacts with 312 health services' (Chapter XXI), and 'Codes for special purposes' (Chapter XXII). The ICD-10 313 codes were then converted into Phecodes (v.1.2) [32] which combine correlated ICD codes into 314 a distinct code and improve alignment with diseases commonly used in clinical practice.

315 For binary traits, we removed phenotypes with fewer than 100 cases, and for continuous traits, those with fewer than 100 participants were excluded. Depending on the phenotype, we 316 317 employed various regression models including binary logistic regression, ordinal logistic regression, multinomial logistic regression, and linear regression. All analyses included age, 318 319 sex, and first five PCs as covariates. Phenome-wide significance threshold was set at  $p=2.9 \times 10^{-5}$  based on the number of phenotypes. 320

321

#### 322 Variant allelic fraction

323 To investigate whether some gene-level associations are enriched for somatic variants, we 324 computed the variant allele frequency (VAF) for each heterozygous sample, reporting the mean 325 VAF and VAF distribution per gene per variant class. VAF is defined as the number of reads 326 with an alternate allele divided by the read depth at a given variant position. We also calculated 327 the confidence interval for the mean VAF per gene using 10,000 bootstrap samples to ensure

- 328 robust statistical analysis.
- 329

### 330 Discussion

331 In this study, we report several known and novel findings related to genetic risks associated

332 with longevity analyzing 393,833 European participants from the UKB. In the common variant

333 GWAS, three independent loci associated with increased mortality risk were identified. In the

334 gene-based analysis of rare non-synonymous variants, 17 genes had their burden/SKAT-O test

335 associated with longevity.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.30.24311226; this version posted August 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

336 Consistent with previous reports, rs429358, determining the APOE-e4 allele dosage, was 337 associated with decreased lifespan across both sexes. APOE-E4 is well known for its 338 associations with Alzheimer's Disease [33] and cardiovascular disease [34]. In our dataset, the 339 proportion of  $\varepsilon 4$  carriers was significantly higher for deaths caused by 'Disease of the 340 circulatory system' and 'Diseases of the nervous system' compared to the general prevalence 341 of  $\varepsilon$ 4 carriers, which could explain the effect of  $\varepsilon$ 4 on longevity. Examining the subcategories 342 of these ICD-10 chapters, 'Disease of the circulatory system' includes cardiovascular disease 343 (I51.6), while 'Diseases of the nervous system' covers Alzheimer's disease (G30). We also 344 identified a GWS association at the ZSCAN23 locus, which had not been previously reported. 345 Our colocalization analysis revealed that the longevity-associated signal colocalizes with a 346 ZSCAN23 eQTL in pancreatic tissue with increased expression observed in minor allele 347 carriers. Although the role of ZSCAN23 remains unclear, recent studies have linked its 348 expression to pancreatic tumors, supporting our colocalization findings [35]. For sex-specific 349 GWAS, a GWS association specific to males was found between MUC5AC and MUC5B, 350 which highly colocalizes with a MUC5B eOTL in lung tissue and many studies have linked 351 this variant to pulmonary disease like idiopathic pulmonary fibrosis [36, 37] and COVID-19 352 [38, 39]. Previously reported SNP associations with longevity were concordant in our dataset but none of these passed the GWAS suggestive threshold ( $p=1.0 \times 10^{-5}$ ) except for those at 353 the APOE locus. This phenomenon likely resulted from previous studies relying on proxy data 354 355 such as parental age at death, which may capture a different set of genetic factors than direct 356 proband mortality data.

357 In our gene-based rare variant analysis, 17 genes achieved gene-wide significance (p  $<7.4 \times 10^{-7}$ ) in either the burden or SKAT-O test. Four of these, TET2, ATM, BRCA2, and 358 359 BRCA1, were reported in a previous rare-variant analysis of longevity in UKB [9]. We 360 identified 13 novel genes associated with longevity-CKMT1B, ASXL1, DNMT3A, SF3B1, PTEN, SOX21, TP53, SRSF2, Clorf52, CHL1, IDH2, RLIM, and TERT— when assessing 361 362 variants causing genetic LoF or missense variants classified as pathogenic by REVEL or 363 AlphaMissense. Of note, LoF and missense variant analyses identified mostly separate genes 364 with only one overlap (TET2). This supports the use of both categories in rare variant analyses 365 and may indicate that missense variants as classified by AlphaMissense capture a wider range of variation missed when only assessing LoF variants, which are generally interpreted as 366 367 resulting in haploinsufficiency. Importantly, missense variants may lead to increased or 368 decreased protein function. In our analyses, IDH2 was not gene-wide significant with the burden test ( $p=1.9 \times 10^{-4}$ , Table 1) but was highly significant with SKAT-O ( $p=5.3 \times 10^{-39}$ , 369 Table 1). Since SKAT-O does not lose power when variants have differing directions of effect, 370 371 this suggests that different mutations in IDH2 can lead to either increased or decreased 372 longevity. These results underline the gain in information achieved when studying rare 373 missense variants as well as LoF using appropriate statistical techniques.

374 Strikingly, most of the genes we identified carrying longevity-associated rare variants have 375 been previously linked to cancer. TET2, ASXL1, DNMT3A, and SF3B1 are all known to harbor 376 causal leukemia variants [40-43], and somatic variants in SRSF2 have been described in 377 myelodysplastic syndrome [44]. ATM, BRCA2, and BRCA1 mutations have been well 378 characterized in breast, ovarian, and other cancers [45-47]. RLIM appears to be a regulator of 379 estrogen-dependent transcription, an important pathway in breast cancer [48], and has been 380 recently described as a potential tumor suppressor [49]. PTEN and TP53 are well studied due 381 to their critical role in genomic stability and are the two most mutated genes in human cancer 382 [50]. IDH2 is also frequently mutated in many kinds of cancer [51]. The antisense long noncoding RNA SOX21-AS1, but not SOX21, has been linked to oral, cervical, and breast 383 384 cancer [52-54]. A recent study found potential for CKMT1B expression as a prognostic

medRxiv preprint doi: https://doi.org/10.1101/2024.07.30.24311226; this version posted August 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 385 biomarker in glioma [55]; similarly, alterations in CHL1 expression have been associated with development and metastasis of many types of cancer [56]. Finally, variation in both the coding 386 and promoter sequences of *TERT* has been associated with a variety of cancer types [57, 58]. 387
- 388 Our PheWAS results also suggest that most of these genes are associated with cancer,
- 389 specifically blood-based tumors such as myeloid leukemia. Combined with the common
- 390 ZSCAN23 locus we identified, associated with pancreatic tumors, this points to cancer being
- 391 the major genetic factor currently affecting lifespan in UKB. This is consistent with a previous
- 392 study of healthspan that found cancer to be the first emerging disease in over half of disease
- 393 cases in UKB [59]. These results likely reflect the characteristics of the cohort, comprised of
- 394 predominantly middle-aged individuals, with age-at-death ranging from 40.9 to 85.2 years and
- 395 last-known ages between 52.6 and 88.7 years.
- 396 For sex-specific rare variant analyses, we identified six novel genes (CDKN1A, PTPRK, 397 COA7, TG, NMNAT2 and PITRM1) in males and three genes (PORCN, UGT1A8 and OLIG1)
- 398 in females. Some of these genes have been found to associate with sex-specific diseases. In one
- 399 study, advanced prostate cancer patients had a higher frequency of a variant on the 3'UTR of
- 400 CDKN1A [60] and the gene has received attention as a potential therapeutic target for prostate
- 401 cancer [61]. PORCN is located on the X chromosome and mutations on it can cause Goltz-
- 402 Gorlin Syndrome [62], but it has also been found to regulate a signaling pathway that controls cancer cell growth [63]. UGT1A8 expression is altered in endometrial cancer [64] and amino
- 403 404 acid substitutions in it may modulate estradiol metabolism leading to increased risk of breast
- 405 and endometrial cancer [65].
- 406 Since UKB collected DNA from peripheral blood mononuclear cell samples, we explored 407 whether the variants were potentially of somatic origin, picked up by WES genotyping due to 408 CHIP. The VAF distribution of variants included in our analysis emphasizes that several 409 associations are likely linked to CHIP, and notably include the well-established CHIP-related 410 genes TET2, ASLX1, DNMT3A, SF3B1, TP53 and SRSF2. While WES heterozygote genotypes
- 411 for these variants will not include all variants with some degree of CHIP within these genes (as
- evidenced by many more individuals having non-zero alternate allele count at these locations, 412 413 data not shown), it does capture CHIP-related somatic variants sufficiently to establish robust
- 414 associations with longevity. In UKB the mean duration between the primary visit (blood draw
- date) and death is currently 9.2 years (+ 3.8) and suggests that WES screening for CHIP 415
- 416 variants may be used as a precision health tool to contribute to earlier cancer detection by 417 assessing individuals with higher susceptibility risks. In addition to known cancer variants,
- 418 such as breast cancer-related BRCA1/BRCA2, our study highlights novel associations that
- 419 should be considered in cancer susceptibility screenings.
- 420 By combining large-scale GWAS with rare variant analysis, this study enhances our 421 understanding of the genetic basis of human longevity. Our results emphasize the importance 422 of understanding the genetic factors driving the most prevalent causes of mortality on a 423 population level, highlighting the potential for early genetic testing to identify germline and 424 somatic variants that place some individuals at risk of early death. Understanding the biological 425 pathways through which these genes influence cancer and aging, as well as the environmental 426 factors interacting with these pathways, will be essential for developing therapeutic targets 427 aimed at extending healthy lifespan. Our study's implications thus extend beyond genetics, as 428 they touch on the broader aspects of health care, public health policy, and preventive strategies 429 against age-related diseases.
- In conclusion, this study enhances our understanding of the genetic basis of human longevity 430
- by combining large-scale GWAS with detailed rare variant analysis. The novel loci identified 431
- 432 warrant further exploration to understand their biological roles and interactions with

environmental factors, which will be crucial for unraveling the complex nature of aging and 433 developing strategies to mitigate its adverse effects. 434

### **Figures and Tables** 435

### 436

437 Figure 1. Common variant GWAS of longevity. (A) Manhattan plot. (B) The proportion of 438 cause of death for the top 4 categories, each accounting for more than 5% of total deaths) (C) 439 Association of causes of death with APOE-ɛ4 genotype. (D) Locuszoom and (E) colocalization plots at the ZSCAN23 locus, colocalized with ZSCAN23 eQTL in pancreatic tissue in GTEx. 440 441 PP4: posterior probability of colocalization.



#### 444 Figure 2. Rare variant burden association with longevity, considering loss-of-functions (A) and Alpha Missense pathogenic variants (B). Novel genes are highlighted in red. 445





#### 448 Figure 3. Survival curves comparing carriers and non-carriers of variants on genes with a significant burden of loss-of-function (A) and AlphaMissense pathogenic (B) variants. 449



(A) Loss of Function СКМТ1В ASXL1 1.0 Survival Probability 0.50 0.25 0.75 Survival Probability 0.50 HR = 3.9, p = 2.1x10 HR = 2.2, p = 3.8x10 0.00 0.00 60 Age 60 Age 50 80 90 80 90 40 70 (B) Alpha Missense



# **Supplementary Figure 1. Phenome-wide association of rs13190937 on** *ZSCAN23.* This analysis is based on PheWeb (https://pheweb.org/UKB-Neale/).



medRxiv preprint doi: https://doi.org/10.1101/2024.07.30.24311226; this version posted August 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

457 Supplementary Figure 2. Sex-stratified common variant GWAS of longevity. Manhattan 458 plot in males (A), and females (B). Locuszoom (C) and colocalization (D) plots at the MUC5B 459 locus in males, colocalized with MUC5B eQTL in lung tissue in GTEx. PP4: posterior probability of colocalization. (E) Phenom-wide association of rs35705950. This analysis is 460 based on PheWeb (https://pheweb.org/UKB-Neale/). 461

![](_page_15_Figure_3.jpeg)

463 464

![](_page_15_Figure_4.jpeg)

#### 466 Supplementary Figure 3. Rare variant SKAT-O association with longevity considering 3

categories: Loss-of-function (A), Alpha Missense (B), and REVEL (C). Novel genes are 467 468 highlighted in red.

469

![](_page_16_Figure_6.jpeg)

### Supplementary Figure 4. Rare variant burden association with longevity considering 471

472 **REVEL pathogenic missense variants.** Novel genes are highlighted in red.

![](_page_17_Figure_5.jpeg)

Supplementary Figure 5. Sex-stratified rare variant burden association with 477 longevity considering 3 categories for each sex: Loss-of-function (A), Alpha Missense (B), 478

and REVEL (C). Novel genes are highlighted in red. 479 480

![](_page_18_Figure_4.jpeg)

#### 482 Supplementary Figure 6. Sex-stratified rare variants SKAT-O association with longevity considering 3 categories for each sex: Loss-of-function (A), Alpha Missense (B), 483

and REVEL (C). Novel genes are highlighted in red. 484

485

![](_page_19_Figure_5.jpeg)

487 Supplementary Figure 7. Survival curves comparing carriers and non-carriers of 488 variants considered on genes with a significant burden of loss-of-function (TET2, ATM, BRCA2 and BRCA1) (A), AlphaMissense pathogenic (B) variants (TET2), missense 489 490 variants predicted by REVEL (DNMT3A, PTEN and TP53) (C)

### 491

![](_page_20_Figure_4.jpeg)

Supplementary Figure 8. Phenome-wide association of the burden of rare variants at the 

nine novel genes identified in our burden test. Variants considered correspond to loss-of-function and Alpha missense defined variants. P-values less than  $1.0 \times 10^{-50}$  are capped at 50. 

![](_page_21_Figure_5.jpeg)

#### 502 Supplementary Figure 9. Variant allelic fraction distribution per gene for variants considered in each category: Loss-of-function (A) and Alpha Missense (B). 503

![](_page_22_Figure_3.jpeg)

![](_page_22_Figure_4.jpeg)

Count

35

10

0+

VAF

SRSF2

VAF

Mean VAF (SD) 0.30 (0.11)

5

4 Count

S Count

Mean VAF (SD) 0.45 (0.11)

0.6 VAF

VAF

тр53

VAR

Mean WAF (SD) 0.28 (0.14)

80

40

20

12

10 -6 Count

Count 09

20

15 Count

1

2.00

1.75 -1.50 -1.25 -<sup>tu</sup>g 1.00 -

0.75

0.25 0.00 RLIM

0.4 0.6 VAF

Mean VAF (SD) 0.44 (0.41)

2.0

tin 1.5

1.0

0.5

0.0

0.8

VAF

505

15

0+

Count S

VAF

VAF

Mean VAF (SD) 0.49 (0.06)

Count

SKAT-O Burden Variant Class Chr Gene # of variants # of carriers p-value p-value  $3.8\times10^{-30}$  $3.4 \times 10^{-54}$ 4 TET2 243 563 11 ATM 247 1,170  $6.0\times10^{-10}$  $4.8 \times 10^{-11}$  $1.3 \times 10^{-34}$  $1.2 \times 10^{-42}$ 13 BRCA2 245 1,271 LoF  $4.5 \times 10^{-7}$  $1.8 \times 10^{-6}$ 15 CKMT1B 15 40  $4.9 \times 10^{-12}$ 17 BRCA1 120 456  $1.3 \times 10^{-11}$ 20 72  $2.3\times10^{-44}$  $2.9\times10^{-46}$ ASXL1 533 1 Clorf52 23 175  $4.5 \times 10^{-5}$  $2.1 \times 10^{-7}$  $1.8 \times 10^{-10}$ 2 1,229  $1.4 \times 10^{-9}$ DNMT3A 167 2 SF3B1 195  $6.7 \times 10^{-12}$  $2.5 \times 10^{-16}$ 64  $1.1 \times 10^{-6}$ 3  $5.0 \times 10^{-7}$ CHL1 33 3,666 4  $4.2 \times 10^{-7}$  $7.4 \times 10^{-7}$ 159 826 TET2 Alpha Missense 10 PTEN 50 71  $1.0 \times 10^{-8}$  $3.9 \times 10^{-11}$  $2.9 \times 10^{-8}$  $6.7 \times 10^{-9}$ 13 52 463 SOX21 15 IDH2 89 349  $1.9 \times 10^{-4}$  $5.3 \times 10^{-39}$ 17 **TP53** 90  $3.1\times10^{-15}$  $2.5\times10^{-16}$ 35 17  $9.8 \times 10^{-89}$  $8.3 \times 10^{-108}$ SRSF2 14 141 RLIM 25 51  $8.8 \times 10^{-7}$  $3.7 \times 10^{-9}$ Х

# Table 1. Significant genes for rare variants association with burden and SKAT-O tests ( $p < 7.4 \times 10^{-7}$ ). Gene names in bold font represent novel associations.

LoF: Loss of Function; Chr: chromosome

Variant Class	Chr	Gene	Variant	MA	MAC	AM	HR	<i>p</i> -value	Reported
	4	TET2	rs370735654	Т	17	-	7.0	$5.6 \times 10^{-9}$	-
	11	ATM	rs587779834	А	113	-	2.5	$2.7 \times 10^{-5}$	-
	13	BRCA2	rs80359520	С	10	-	6.1	$1.8 \times 10^{-6}$	Breast Cancer [66]
LoF	15	CKMT1B	rs1355844751	Т	8	-	4.9	$5.9 \times 10^{-3}$	-
	17	BRCA1	rs80357508	С	44	-	2.8	$3.5 \times 10^{-3}$	-
	20	ASXL1	rs750318549	AG	201	-	2.5	$2.3 \times 10^{-15}$	-
	1	Clorf52	rs769009649	А	62	0.876	3.2	$7.4 \times 10^{-7}$	-
	2	DNMT3A	rs147001633	Т	269	0.995	1.8	$3.7 \times 10^{-5}$	Leukemia [67, 68]
	2	SF3B1	rs377023736	А	12	0.999	6.0	$8.5 \times 10^{-8}$	-
	3	CHL1	rs116421102	С	1,842	0.745	1.3	$2.5 \times 10^{-5}$	-
	4	TET2	rs76428136	G	5	0.913	8.1	$2.9 \times 10^{-4}$	-
Alpha Missense	10	PTEN	rs587782350	Т	3	0.941	20.4	$2.6 \times 10^{-3}$	-
	13	SOX21	rs1172148601	А	67	0.856	2.3	$1.7 \times 10^{-3}$	-
	15	IDH2	rs121913502	Т	45	0.987	5.7	$1.0 \times 10^{-20}$	Leukemia [68, 69]
	17	TP53	rs11540652	Т	5	0.996	10.0	$6.6 \times 10^{-5}$	Gastric Cancer [70], Ovarian Cancer [71]
	17	SRSF2	rs751713049	Т	51	0.982	5.8	$1.9 \times 10^{-26}$	-
	Х	RLIM	X:74592998:C:A	А	3	0.970	3.9	$1.3 \times 10^{-3}$	-

Table 2. Lead variant association per gene among significant genes in the burden and SKAT-O tests. Only variants with at least 3 minor alleles are reported.

Chr: chromosome; MAC: minor allele count; AM: AlphaMissense score; HR: hazard ratio

		All			Male			Female	
	Total	Living	Deceased	Total	Living	Deceased	Total	Living	Deceased
Ν	393,833	358,282	35,551	180,970	159,911	21,059	212,863	198,371	14,492
Last known age	70.8 ± 7.9	$70.7 \\ \pm 8.0$	71.2 ± 7.5	70.9 ± 8.0	$70.8 \\ \pm 8.1$	71.3 ± 7.4	70.7 ± 7.9	70.7 ± 7.9	71.1 ± 7.6
APOE ε4 carrier	113,437 (28.8%)	102,360 (28.6%)	11,077 (31.2%)	52,190 (28.8%)	45,635 (28.5%)	6,555 (31.1%)	61,247 (28.8%)	56,725 (28.6%)	4,522 (31.2%)

# Supplementary Table 1. Demographics of European ancestry in the analyses.

Supplementary Table 2. Significant genes for burden and SKAT-O association of rare variants, considering missense variants with REVEL > 75. Gene names in bold font represent novel associations in REVEL.

Variant Class	Chr	Gene	# of variants	# of carriers	Burden <i>p</i> -value	SKAT-O <i>p</i> -value
	2	DNMT3A	116	831	$6.6 \times 10^{-9}$	$3.5 \times 10^{-8}$
<b>DEVEL</b> $(>75)$	5	TERT	31	60	$2.6 \times 10^{-3}$	$8.1 \times 10^{-10}$
KEVEL (>75)	10	PTEN	42	45	$6.6 \times 10^{-8}$	$3.6 \times 10^{-10}$
	17	TP53	47	173	$6.2 \times 10^{-9}$	$6.5 \times 10^{-9}$

Variant Class	Chr	Gene	# of variants	# of carriers	Burden <i>p</i> -value	SKAT-O <i>p</i> -value
	4	TET2	162	280	$4.1 \times 10^{-20}$	$1.5 \times 10^{-32}$
	6	<b>CDKN1A</b>	8	33	$1.1 \times 10^{-4}$	$6.3 \times 10^{-8}$
	6	PTPRK	26	40	$5.9 \times 10^{-3}$	$4.5 \times 10^{-7}$
Lof	11	ATM	318	520	$2.6 \times 10^{-10}$	$2.0\times10^{-10}$
	13	BRCA2	172	596	$2.3 \times 10^{-16}$	$1.5 \times 10^{-19}$
	20	ASXL1	59	347	$5.4 \times 10^{-36}$	$6.4 \times 10^{-37}$
	1	Clorf52	19	76	$2.2 \times 10^{-5}$	$2.7 \times 10^{-10}$
	1	COA7	8	11	$1.0 \times 10^{-4}$	$3.1 \times 10^{-8}$
	2	SF3B1	43	122	$1.6 \times 10^{-11}$	$2.8\times10^{-14}$
Alpha Missense	4	TET2	107	405	1.1 × 10 <sup>-8</sup>	$1.6 \times 10^{-8}$
(>70)	8	TG	113	657	$2.4 \times 10^{-7}$	$1.2 \times 10^{-6}$
	15	IDH2	58	171	$2.2 \times 10^{-3}$	$5.5 \times 10^{-29}$
	17	TP53	24	48	$1.5 \times 10^{-9}$	$1.1 \times 10^{-9}$
	17	SRSF2	10	104	$5.4 \times 10^{-63}$	$1.7 \times 10^{-70}$
DEVEL (> 75)	1	NMNAT2	21	34	$1.2 \times 10^{-4}$	$1.9 \times 10^{-8}$
KEVEL (≥/5)	10	PITRM1	6	10	$1.5 \times 10^{-6}$	$3.6 \times 10^{-8}$

### Supplementary Table 3. Significant genes for burden and SKAT-O association of rare variants in males. Genes in bold font represent novel associations in males.

Variant Class	Chr	Gene	# of variants	# of carriers	Burden <i>p</i> -value	SKAT-O <i>p</i> -value
	4	TET2	151	283	$7.8 \times 10^{-11}$	$5.1 \times 10^{-24}$
	13	BRCA2	182	675	$1.2 \times 10^{-20}$	$4.8 \times 10^{-27}$
Lof	17	BRCA1	80	217	$3.6 \times 10^{-12}$	$2.4 \times 10^{-11}$
	20	ASXL1	46	186	$1.1 \times 10^{-6}$	$2.0 \times 10^{-7}$
	2	DNMT3A	135	671	$7.6 \times 10^{-9}$	$2.3 \times 10^{-10}$
	5	TERT	22	27	$1.7 \times 10^{-3}$	$2.2 \times 10^{-7}$
Alpha Missense	13	SOX21	34	251	$2.0 \times 10^{-7}$	$1.6 \times 10^{-7}$
(>70)	17	SRSF2	10	37	$3.3 \times 10^{-16}$	$8.4 \times 10^{-27}$
	17	TP53	23	52	$1.1 \times 10^{-7}$	$1.8 \times 10^{-8}$
	Х	PORCN	11	32	$5.6 \times 10^{-4}$	$3.7 \times 10^{-7}$
DEVEL (575)	2	UGT1A8	2	18	$2.8 \times 10^{-7}$	$2.8 \times 10^{-7}$
REVEL (>/5)	21	OLIG1	7	18	$1.3 \times 10^{-5}$	$7.0 \times 10^{-7}$

### Supplementary Table 4. Significant genes for burden and SKAT-O association of rare variants in females. Genes in bold font represent novel associations in females.

Variant Class	Chr	Gene	Variant	MA	MAC	AM	HR	<i>p</i> -value	Reported
	2	DNMT3A	rs367909007	G	14	0.983	4.3	$1.2 \times 10^{-3}$	-
	5	TERT	rs1043358053	С	5	0.926	11.9	$7.4 \times 10^{-7}$	-
REVEL (>75)	10	PTEN	rs587782350	С	3	0.941	20.4	$2.6 \times 10^{-3}$	-
	17	TP53	rs11540652	Т	5	0.996	10.0	$6.6 \times 10^{-5}$	Gastric Cancer [70], Ovarian Cancer [71]

**Supplementary Table 5. Lead variant association per gene among significant genes in the burden and SKAT-O tests.** Only significant variant associations with at least 3 minor allele counts per gene are reported in this table.

Variant Class	Chr	Gene	# of subjects	# of variants	Mean VAF (SD)
	4	TET2	266	133	0.33 (0.14)
	11	ATM	734	128	0.46 (0.10)
LE	13	BRCA2	1,061	162	0.44 (0.12)
LOF	15	CKMT1B	29	8	0.56 (0.17)
	17	BRCA1	302	74	0.46 (0.09)
	20	ASXL1	502	30	0.32 (0.11)
	1	Clorf52	87	11	0.50 (0.07)
	2	DNMT3A	593	33	0.24 (0.10)
	2	SF3B1	23	5	0.31 (0.16)
	3	CHL1	12	3	0.37 (0.18)
	4	TET2	123	41	0.36 (0.15)
Alpha Missense	10	PTEN	5	3	0.39 (0.04)
	13	SOX21	22	6	0.49 (0.06)
	15	IDH2	46	14	0.45 (0.11)
	17	TP53	19	7	0.28 (0.14)
	17	SRSF2	164	6	0.30 (0.11)
	Х	RLIM	4	2	0.44 (0.41)

# Supplementary Table 6. Mean variant allelic fraction per gene across participants included in the corresponding gene-level Burden/SKAT-O analysis.

### Acknowledgements

This research has been conducted using the UK Biobank Resource under application number 45420. We thank all the participants and researchers of UK Biobank for making these data open and accessible to the research community.

# Authors' contributions

J.P conducted all the analyses, prepared all figures and wrote the manuscript. A.P.T contributed to the manuscript writing. L.T provided critical comment on the manuscript. M.D.G and Y.L.G planned, organized and supervised the entire study and revised the manuscript. All authors have approved the submitted version.

### Funding

This research was supported by the Dean's Postdoctoral Fellowship at the School of Medicine, Stanford University. Additionally, this research was partially supported by the Biostatistics Shared Resource (B-SR) of the NCI-sponsored Stanford Cancer Institute: P30CA124435 and by the following NIH funding source of Stanford's Center for Clinical and Translational Education and Research award, under the Biostatistics, Epidemiology and Research Design (BERD) Program: 1UM1TR004921-01.

### Data availability

GWAS summary statistics for this study are available in the GWAS Catalog. Data supporting the findings of this study are available from the UK Biobank (UKB). Access to these data is available from the authors with UKB permission

### **Code availability**

The codes used for analyses in the present study are available at the following link: https://github.com/Junkkkk/Lifespan-studies

**Consent for publication** Not applicable.

### **Competing interests**

The authors declare that they have no competing interests.

# References

- 1. Passarino, G., F. De Rango, and A. Montesanto, *Human longevity: Genetics or Lifestyle? It takes two to tango.* Immunity & Ageing, 2016. **13**: p. 1-6.
- 2. Ruby, J.G., et al., *Estimates of the Heritability of Human Longevity Are Substantially Inflated due to Assortative Mating.* Genetics, 2018. **210**(3): p. 1109-1124.
- v, B.H.J., et al., *Genetic influence on human lifespan and longevity.* Hum Genet, 2006.
   **119**(3): p. 312-21.
- 4. van den Berg, N., et al., *Longevity defined as top 10% survivors and beyond is transmitted as a quantitative genetic trait.* Nature Communications, 2019. **10**(1): p. 35.
- 5. Ryu, S., et al., *Genetic landscape of APOE in human longevity revealed by high-throughput sequencing.* Mech Ageing Dev, 2016. **155**: p. 7-9.
- Sebastiani, P., et al., APOE Alleles and Extreme Human Longevity. J Gerontol A Biol Sci Med Sci, 2019. 74(1): p. 44-51.
- 7. Joshi, P.K., et al., *Variants near CHRNA3/5 and APOE have age- and sex-related effects on human lifespan.* Nature Communications, 2016. **7**(1): p. 11174.
- 8. Joshi, P.K., et al., *Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity.* Nature Communications, 2017. **8**(1): p. 910.
- Liu, J.Z., et al., *The burden of rare protein-truncating genetic variants on human lifespan.* Nature Aging, 2022. 2(4): p. 289-294.
- 10. Liu, J.Z., Y. Erlich, and J.K. Pickrell, *Case–control association mapping by proxy using family history of disease.* Nature Genetics, 2017. **49**(3): p. 325-331.
- 11. Bae, H., et al., *A genome-wide association study of 2304 extreme longevity cases identifies novel longevity variants.* International Journal of Molecular Sciences, 2022. **24**(1): p. 116.
- 12. Sebastiani, P., et al., *Four Genome-Wide Association Studies Identify New Extreme Longevity Variants.* The Journals of Gerontology: Series A, 2017. **72**(11): p. 1453-1464.
- 13. Deelen, J., et al., *A meta-analysis of genome-wide association studies identifies multiple longevity genes.* Nature Communications, 2019. **10**(1): p. 3669.
- 14. Therneau, T.M., P.M. Grambsch, and T.R. Fleming, *Martingale-based residuals for survival models*. Biometrika, 1990. **77**(1): p. 147-160.
- 15. Gagliano Taliun, S.A., et al., *Exploring and visualizing large-scale genetic associations by using PheWeb.* Nature Genetics, 2020. **52**(6): p. 550-552.
- 16. Baer, C., et al., "Somatic" and "pathogenic" is the classification strategy applicable in times of large-scale sequencing? Haematologica, 2019. **104**(8): p. 1515-1520.
- Sudlow, C., et al., UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med, 2015. 12(3): p. e1001779.
- Bycroft, C., et al., *The UK Biobank resource with deep phenotyping and genomic data*. Nature, 2018. **562**(7726): p. 203-209.
- 19. Purcell, S., et al., *PLINK: a tool set for whole-genome association and population-based linkage analyses.* The American journal of human genetics, 2007. **81**(3): p. 559-575.

- Cox, D.R., *Regression models and life-tables.* Journal of the Royal Statistical Society: Series
   B (Methodological), 1972. 34(2): p. 187-202.
- 21. Therneau, T., *A package for survival analysis in S.* R package version, 2015. **2**(7): p. 2014.
- 22. Pruim, R.J., et al., *LocusZoom: regional visualization of genome-wide association scan results.* Bioinformatics, 2010. **26**(18): p. 2336-2337.
- 23. Mohammadi Pejman 5 6 Park YoSon 11 Parsana Princy 12 Segrè Ayellet V. 1 Strober Benjamin J. 9 Zappala Zachary 7 8, G.C.L.a.A.F.B.A.A.C.S.E.D.J.R.H.Y.J.B., et al., *Genetic effects on gene expression across human tissues.* Nature, 2017. **550**(7675): p. 204-213.
- 24. Giambartolomei, C., et al., *Bayesian test for colocalisation between pairs of genetic association studies using summary statistics.* PLoS genetics, 2014. **10**(5): p. e1004383.
- 25. Liu, B., et al., *Abundant associations with gene expression complicate GWAS follow-up.* Nature Genetics, 2019. **51**(5): p. 768-769.
- 26. Szustakowski, J.D., et al., *Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank.* Nature genetics, 2021. **53**(7): p. 942-948.
- 27. McLaren, W., et al., *The Ensembl Variant Effect Predictor.* Genome Biology, 2016. **17**(1): p. 122.
- 28. Cheng, J., et al., *Accurate proteome-wide missense variant effect prediction with AlphaMissense.* Science, 2023. **381**(6664): p. eadg7492.
- 29. Ioannidis, N.M., et al., *REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants.* Am J Hum Genet, 2016. **99**(4): p. 877-885.
- 30. Lee, S., et al., Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am J Hum Genet, 2012.
  91(2): p. 224-37.
- 31. Wu, M.C., et al., *Rare-variant association testing for sequencing data with the sequence kernel association test.* Am J Hum Genet, 2011. **89**(1): p. 82-93.
- 32. Wu, P., et al., *Mapping ICD-10 and ICD-10-CM codes to phecodes: workflow development and initial evaluation.* JMIR medical informatics, 2019. **7**(4): p. e14325.
- 33. Bellenguez, C., et al., *New insights into the genetic etiology of Alzheimer's disease and related dementias.* Nature Genetics, 2022. **54**(4): p. 412-436.
- 34. Mahley, R.W., *Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders.* Journal of Molecular Medicine, 2016. **94**(7): p. 739-746.
- 35. Du, Q., et al., *Epigenetic silencing ZSCAN23 promotes pancreatic cancer growth by activating Wnt signaling.* Cancer Biology & Therapy, 2024. **25**(1): p. 2302924.
- 36. Lee, M.-G. and Y.H. Lee, A meta-analysis examining the association between the MUC5B rs35705950 T/G polymorphism and susceptibility to idiopathic pulmonary fibrosis.
   Inflammation Research, 2015. 64(6): p. 463-470.
- 37. Nakano, Y., et al., *MUC5B promoter variant rs35705950 affects MUC5B expression in the distal airways in idiopathic pulmonary fibrosis.* American journal of respiratory and critical care medicine, 2016. **193**(4): p. 464-466.
- 38. van Moorsel, C.H., et al., *The MUC5B promoter polymorphism associates with severe*

COVID-19 in the European population. Frontiers in medicine, 2021. 8: p. 668024.

- 39. Verma, A., et al., *A MUC5B gene polymorphism, rs35705950-T, confers protective effects against COVID-19 hospitalization but not severe disease or mortality.* American journal of respiratory and critical care medicine, 2022. **206**(10): p. 1220-1229.
- 40. Quivoron, C., et al., *TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis.* Cancer Cell, 2011.
   20(1): p. 25-38.
- 41. Abdel-Wahab, O., et al., *ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression.* Cancer Cell, 2012. **22**(2): p. 180-193.
- 42. Yang, L., R. Rau, and M.A. Goodell, *DNMT3A in haematological malignancies.* Nature Reviews Cancer, 2015. **15**(3): p. 152-165.
- 43. Wang, L., et al., *<i>SF3B1</i> and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia.* New England Journal of Medicine, 2011. **365**(26): p. 2497-2506.
- 44. Kim, E., et al., *SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.* Cancer Cell, 2015. **27**(5): p. 617-630.
- 45. Cremona, C.A. and A. Behrens, *ATM signalling and cancer.* Oncogene, 2014. **33**(26): p. 3351-3360.
- 46. Wooster, R., et al., *Identification of the breast cancer susceptibility gene BRCA2.* Nature, 1995. **378**(6559): p. 789-792.
- 47. Ford, D., et al., *Risks of cancer in BRCA1-mutation carriers.* The Lancet, 1994. **343**(8899): p. 692-695.
- 48. Johnsen, S.A., et al., *Regulation of Estrogen-Dependent Transcription by the LIM Cofactors CLIM and RLIM in Breast Cancer.* Cancer Research, 2008. **69**(1): p. 128-136.
- 49. Gao, R., et al., *E3 Ubiquitin Ligase RLIM Negatively Regulates c-Myc Transcriptional Activity* and Restrains Cell Proliferation. PLOS ONE, 2016. **11**(9): p. e0164086.
- 50. Yin, Y. and W.H. Shen, *PTEN: a new guardian of the genome.* Oncogene, 2008. **27**(41): p. 5443-5453.
- 51. Yang, H., et al., *IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives.* Clinical Cancer Research, 2012. **18**(20): p. 5562-5571.
- 52. Yang, C.-M., et al., *Aberrant DNA hypermethylation-silenced SOX21-AS1 gene expression and its clinical importance in oral cancer.* Clinical Epigenetics, 2016. **8**(1): p. 129.
- 53. Zhang, X., et al., *Long noncoding RNA SOX21-AS1 promotes cervical cancer progression by competitively sponging miR-7/VDAC1.* Journal of Cellular Physiology, 2019. **234**(10): p. 17494-17504.
- Sheng, X.-Y., et al., Long-Chain Non-Coding SOX21-AS1 Promotes Proliferation and Migration of Breast Cancer Cells Through the PI3K/AKT Signaling Pathway. Cancer Management and Research, 2020. 12(null): p. 11005-11014.
- 55. Shi, H., et al., *CKMT1B is a potential prognostic biomarker and associated with immune infiltration in Lower-grade glioma.* PLOS ONE, 2021. **16**(1): p. e0245524.
- 56. Senchenko, V.N., et al., *Differential expression of CHL1 gene during development of major*

*human cancers.* PloS one, 2011. **6**(3): p. e15612.

- 57. Baird, D.M., *Variation at the TERT locus and predisposition for cancer.* Expert Reviews in Molecular Medicine, 2010. **12**: p. e16.
- 58. Vinagre, J., et al., *Frequency of TERT promoter mutations in human cancers.* Nature Communications, 2013. **4**(1): p. 2185.
- 59. Zenin, A., et al., *Identification of 12 genetic loci associated with human healthspan.* Communications Biology, 2019. **2**(1): p. 41.
- 60. Kibel, A.S., et al., *CDKN1A and CDKN1B Polymorphisms and Risk of Advanced Prostate Carcinoma1.* Cancer Research, 2003. **63**(9): p. 2033-2036.
- 61. Li, S., et al., *miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression.* Oncology Reports, 2017. **37**(1): p. 241-248.
- 62. Lombardi, M.P., et al., *Mutation update for the PORCN gene*. Human Mutation, 2011. **32**(7): p. 723-728.
- 63. Covey, T.M., et al., *PORCN moonlights in a Wnt-independent pathway that regulates cancer cell proliferation.* Plos one, 2012. **7**(4): p. e34532.
- 64. Zhao, F., et al., *The function of uterine UDP-glucuronosyltransferase 1A8 (UGT1A8) and UDP-glucuronosyltransferase 2B7 (UGT2B7) is involved in endometrial cancer based on estrogen metabolism regulation.* Hormones, 2020. **19**: p. 403-412.
- 65. Thibaudeau, J., et al., *Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone.* Cancer research, 2006. **66**(1): p. 125-133.
- Yang, X.R., et al., *Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.* Breast Cancer Res Treat, 2017. 165(3): p. 687-697.
- 67. Clay-Gilmour, A., et al., *Pathogenic and likely pathogenic germline variation in patients with myeloid malignancies and their unrelated HLA-matched hematopoietic stem cell donors.* 2024.
- Petiti, J., et al., *Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach.* International Journal of Molecular Sciences, 2024.
   **25**(7): p. 3631.
- Bayram, D.M., F.M. Lafta, and B.F. Matti, *Impact of IDH Mutations on DNA Methylation of* Acute Myeloid Leukemia Related Genes: A Review Article. Journal of the Faculty of Medicine Baghdad, 2024. 66(1): p. 116-125.
- Hnatyszyn, A., et al., *Mutations in Helicobacter pylori infected patients with chronic gastritis, intestinal type of gastric cancer and familial gastric cancer.* Hereditary Cancer in Clinical Practice, 2024. 22(1): p. 9.
- Richau, C.S., et al., *BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.* Cancer Medicine, 2024.